OBJECTIVE: To investigate postoperatively repairing methods and their clinical effects of the olders over 80 years old with head and facial skin malignancies. METHOD: Eighteen cases of skin cancers in the head and face, whose malignancies were resected with Mohs microscopic surgery, according to the local or systemic condition of patients after surgery we choose different repairing methods: free skin flap grafting in 2 cases, local skin flap transferring 12 cases; including rotation skin flap grafting 6 cases, sliding flap 4 cases, nasolabial flap 2 cases; transposition flap 4 cases. RESULT: Operations of the 18 cases went well without special complications. All of the flaps were alive with partial flap necrosis in 1 case, which was cured 1 month later by dressing changes. During the follow-up period ranged from 6 months to 2 years,no tumor recurred,the functional recovery and appearance were satisfactory. CONCLUSION Choosing operating methods in head and facial skin malignancies should consider patients' age, disease state and general condition. Reparing methods of Head and facial skin malignancies in the advanced ages should be selected according to their specific circumstances, especially the simple, convenient and rapid with less trauma way.
Face ; pathology ; Free Tissue Flaps ; Head ; pathology ; Humans ; Neoplasm Recurrence, Local ; Postoperative Period ; Reconstructive Surgical Procedures ; Skin ; pathology ; Skin Neoplasms ; surgery ; Skin Transplantation

Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults and is poorly controlled. Previous studies have shown that both macrophages and angiogenesis play significant roles in GBM progression, and co-targeting of CSF1R and VEGFR is likely to be an effective strategy for GBM treatment. Therefore, this study developed a novel and selective inhibitor of CSF1R and VEGFR, SYHA1813, possessing potent antitumor activity against GBM. SYHA1813 inhibited VEGFR and CSF1R kinase activities with high potency and selectivity and thus blocked the cell viability of HUVECs and macrophages and exhibited anti-angiogenetic effects both in vitro and in vivo. SYHA1813 also displayed potent in vivo antitumor activity against GBM in immune-competent and immune-deficient mouse models, including temozolomide (TMZ) insensitive tumors. Notably, SYHA1813 could penetrate the blood-brain barrier (BBB) and prolong the survival time of mice bearing intracranial GBM xenografts. Moreover, SYHA1813 treatment resulted in a synergistic antitumor efficacy in combination with the PD-1 antibody. As a clinical proof of concept, SYHA1813 achieved confirmed responses in patients with recurrent GBM in an ongoing first-in-human phase I trial. The data of this study support the rationale for an ongoing phase I clinical study (ChiCTR2100045380).